COPD Inflammatory Markers Review Will Track Links to Lung Function and Physical Performance
Chronic obstructive pulmonary disease carries a burden that extends well beyond airflow obstruction. Inflammation is central to that broader biology, and the protocol published in BMJ Open sets out to examine whether circulating inflammatory markers track with the clinical features that matter most at the bedside: lung function, muscle force, and exercise capacity in people with COPD.
The review is designed around a straightforward clinical question with important mechanistic implications. If systemic inflammation is consistently associated with weaker respiratory mechanics, impaired peripheral muscle strength, and poorer functional tolerance, then inflammatory biomarkers may help explain why some patients decline faster, recover less fully after exacerbations, or struggle despite standard inhaled therapy. In COPD, the lungs and skeletal muscle do not operate in isolation; chronic inflammatory signaling can reach across organ systems and influence conditioning, fatigue, and physical reserve.
One sentence captures the clinical stakes: COPD is not only a disease of airflow limitation, but also a systemic disorder that can erode exercise tolerance and strength.
Why the Review Focuses on Inflammation Beyond the Airways
The protocol rests on a biologically plausible premise. Acute exacerbations of COPD contribute heavily to disease burden, and systemic inflammation can intensify during those episodes. Over time, repeated inflammatory injury may affect skeletal muscle metabolism, reduce functional capacity, and worsen the physiologic reserve needed for walking, climbing stairs, or completing basic activities of daily living. That pathway matters because clinicians often judge COPD severity through spirometry alone, even though many patients experience disabling weakness and reduced exercise performance that are not fully captured by airflow metrics.
The planned review will examine whether inflammatory markers are negatively associated with the outcomes that define this broader phenotype. The included outcomes are deliberately practical: lung function, muscle force, and exercise capacity. Each outcome reflects a different layer of COPD morbidity. Spirometric impairment represents airway disease; muscle force reflects peripheral functional loss; exercise capacity integrates cardiopulmonary stress, skeletal muscle performance, and patient tolerance of exertion.
The protocol also asks whether factors such as hospitalization or participation in an exercise program influence inflammatory marker levels. That second question is clinically important because it links biology to modifiable care pathways. Hospitalization may capture a period of heightened inflammatory stress, while exercise programs may alter inflammatory tone through conditioning and improved muscle efficiency. The review is therefore not limited to observational association alone; it also aims to clarify whether clinical context changes the inflammatory signal itself.
Search Strategy and Evidence Appraisal Plan
Investigators will search Scopus, PubMed, Cochrane, Web of Science, and ProQuest from database inception through February 2023. The search uses a PEO framework: adults with COPD as the population, inflammatory markers as the exposure, and lung function, muscle force, and exercise capacity as outcomes. That structure is appropriate for a protocol centered on associations rather than treatment effects.
Four reviewers, working in pairs, will independently screen studies and extract data that meet the eligibility criteria. Independent dual review reduces the chance that relevant studies are missed or incorrectly excluded, especially when biomarker studies use heterogeneous definitions, different outcome measures, or small samples. The protocol also specifies formal quality assessment. Depending on study design, investigators will apply either Cochrane risk-of-bias version 2 or the Newcastle-Ottawa Scale to judge methodological quality.
This is a sensible choice for a mixed evidence base. Randomized trials and observational studies require different tools because their sources of bias are not the same. In biomarker literature, confounding by disease severity, smoking history, exacerbation status, comorbidity burden, and treatment exposure can distort the apparent relationship between inflammation and function. A structured quality review is essential if pooled estimates are to mean anything clinically.
Pooled Effect Sizes Will Be Standardized Across Heterogeneous Studies
The protocol plans to standardize effect sizes from individual studies to Cohen’s d and then pool them using a random-effects model. In practical terms, that approach recognizes that COPD biomarker studies are unlikely to be uniform. They may measure different inflammatory markers, use different functional tests, and enroll patients across varying stages of disease severity or stability. A random-effects model is appropriate when true effects probably differ from one study to another rather than clustering around a single fixed value.
This choice also reflects the biological reality of COPD. Inflammation is not a single-axis phenomenon, and no single marker is likely to behave identically across every clinical context. A patient sampled after recent hospitalization may not resemble a stable outpatient enrolled in a rehabilitation program. The pooled analysis will therefore need to absorb genuine clinical variation, not just statistical noise.
The protocol does not claim that inflammatory markers will prove useful as stand-alone prognostic tools. It instead positions the evidence review as a way to clarify whether the existing literature supports a measurable relationship between systemic inflammation and functional impairment. If the literature is consistent, that could strengthen the case for biomarker-informed phenotyping. If the literature is inconsistent, the field may need better outcome harmonization, stricter timing around exacerbations, or more precise subgroup definitions before biomarkers can be used meaningfully in routine care.
What the Protocol Can and Cannot Deliver Yet
Because this is a protocol, it does not provide pooled results, effect estimates, or definitive conclusions about causality. Its value lies in the structure of the question and the rigor of the planned synthesis. The review is registered in PROSPERO under CRD42022284446, which adds transparency and reduces the risk of selective reporting after the literature has been examined.
Ethical approval is not required because the review will use publicly available data. The findings are intended for publication in peer-reviewed journals and presentation at conferences once the analysis is complete. For clinicians, the most relevant unresolved issue is whether inflammatory markers consistently mirror the functional losses that shape daily life in COPD. Until the evidence is pooled, the field remains dependent on small, heterogeneous studies that suggest a connection but do not yet define how strong or clinically usable that connection may be.